Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
Liza Chacko(The Royal Free Hospital), Marianna Fontana(Johnson & Johnson (United States)), Adam Ioannou(MACOM (United States)), James Moon(Virginia Mason Medical Center), Daniel Knight(MACOM (United States)), Aviva Petrie(Eastman Dental Hospital), Dorota Rowczenio(Children's Cancer and Leukaemia Group), Claudio Rapezzi(Boston University), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Mattia Riefolo(Azienda USL di Bologna), Ashutosh Wechelakar(MACOM (United States)), Francesco Bandera(IRCCS Policlinico San Donato), Lucia Venneri(MACOM (United States)), Luciano Potena(Azienda USL di Bologna), Philip N. Hawkins(The Royal Free Hospital), James Brown(MACOM (United States)), Charlotte Manisty(National Institutes of Health), Richard P. Steeds(University Hospitals Birmingham NHS Foundation Trust), Janet A. Gilbertson(Children's Cancer and Leukaemia Group), Rishi Patel(MACOM (United States)), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Carol Whelan(Boston University), Jonathan Lazari(The Royal Free Hospital), Yousuf Razvi(MACOM (United States)), Aldostefano Porcari(University of Trieste), Lodovico Buonamici(The Royal Free Hospital), Candida Cristina Quarta(Boston University), William E. Moody(University Hospitals Birmingham NHS Foundation Trust), Ornella Leone(Policlinico S.Orsola-Malpighi), Nina Karia(The Royal Free Hospital), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Beatrice Dal Passo(The Royal Free Hospital)
Cited by 83
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k